Last reviewed · How we verify
Anti-hypertensive drugs — Competitive Intelligence Brief
phase 3
Anti-hypertensive agent (class designation pending specific mechanism)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Anti-hypertensive drugs (Anti-hypertensive drugs) — Universal Research Group. Anti-hypertensive drugs lower blood pressure through various mechanisms including vasodilation, reduced cardiac output, or decreased peripheral vascular resistance.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-hypertensive drugs TARGET | Anti-hypertensive drugs | Universal Research Group | phase 3 | Anti-hypertensive agent (class designation pending specific mechanism) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Anti-hypertensive agent (class designation pending specific mechanism) class)
- Universal Research Group · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-hypertensive drugs CI watch — RSS
- Anti-hypertensive drugs CI watch — Atom
- Anti-hypertensive drugs CI watch — JSON
- Anti-hypertensive drugs alone — RSS
- Whole Anti-hypertensive agent (class designation pending specific mechanism) class — RSS
Cite this brief
Drug Landscape (2026). Anti-hypertensive drugs — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-hypertensive-drugs. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab